Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Open Gastroenterology"
DOI: 10.1136/bmjgast-2025-001925
Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumours, with 5-year survival consistently below 10% and only modest gains from conventional chemotherapy after first-line failure. Although oncogenic KRAS mutations dominate the genomic landscape,… read more here.
Keywords: cancer targeted; targeted therapies; mutations pancreatic; therapies making ... See more keywords